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Abstract: In cells, thymidylate synthases provide the only de novo source of
2′-deoxythymidine-5′-monophosphate (dTMP), required for DNA synthesis. The activity of these
enzymes is pivotal for cell survival and proliferation. Two main families of thymidylate synthases
have been identified in bacteria, folate-dependent thymidylate synthase (TS) and flavin-dependent TS
(FDTS). TS and FDTS are highly divergent enzymes, characterized by exclusive catalytic mechanisms,
involving different sets of cofactors. TS and FDTS mechanisms of action have been recently revised,
providing new perspectives for the development of antibacterial drugs targeting these enzymes.
Nonetheless, some catalytic details still remain elusive. For bacterial TSs, half-site reactivity is still an
open debate and the recent evidences are somehow controversial. Furthermore, different behaviors
have been identified among bacterial TSs, compromising the definition of common mechanisms.
Moreover, the redox reaction responsible for the regeneration of reduced flavin in FDTSs is not
completely clarified. This review describes the recent advances in the structural and functional
characterization of bacterial TSs and FDTSs and the current understanding of their mechanisms of
action. Furthermore, the recent progresses in the development of inhibitors targeting TS and FDTS in
human pathogenic bacteria are summarized.
Keywords: thymidylate synthase; flavin-dependent thymidylate synthase; mechanism of action;
half-site reactivity; inhibitors; selectivity
1. Introduction
Thymidylate synthase is a class of methyltransferase enzymes required for de novo
2′-deoxythymidine-5′-monophosphate (dTMP) synthesis. These enzymes catalyze the methylation of
2′-deoxyuridine-5′-monophosphate (dUMP) using N5,N10-methylentetrahydrofolate (CH2H4folate) as
co-substrate. Thymidylate synthases are pivotal for cell survival and replication since they provide the
unique biosynthetic source of dTMP, essential for DNA synthesis.
In bacteria, two main families of thymidylate synthases are known, folate-dependent thymidylate
synthase (TS, EC 2.1.1.45) and flavin-dependent thymidylate synthase (FDTS, EC 2.1.1.148), encoded by
thyA and thyX genes, respectively [1,2]. TS and FDTS are highly divergent at all structural levels [1,2].
These enzymes are also characterized by exclusive catalytic mechanisms that involve different sets of
cofactors [1–4]. At variance with TS that relies only on CH2H4folate, FDTS requires CH2H4folate, flavin
adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate (NADPH) to perform
its action [1–4]. In the TS-catalyzed reaction, CH2H4folate provides both the methylene group and the
hydride required to convert dUMP in dTMP (Figure 1) [1,5]. Dihydrofolate (H2folate), generated as
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byproduct of the TS reaction, is then converted to tetrahydrofolate (H4folate) through a second enzyme,
dihydrofolate reductase (DHFR, encoded by folA gene) (Figure 1) [5]. On the other hand, FDTSs are
able to combine the TS and DHFR functions, relying on the two additional cofactors, NADPH and FAD
(Figure 1) [2]. FDTSs use CH2H4folate solely as the methyl donor, yielding H4folate (Figure 1) [2,4].
At a later stage, the pathways of TS and FDTS converge in the recycling of the cofactor CH2H4folate
from H4folate, ensured by the enzyme serine hydroxymethyltransferase [5].
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Figure 1. eacti s catalyzed by TS and DHFR (upper panel) and FDTS (lower panel) (TS, PDB
id 3QJ7; DHFR, PDB id 5UIH; FDTS, PDB id 3GCW). In the FDTS catalyzed reaction, the cofactor
FAD is not displayed because it is oxidized and subsequently reduced in each catalytic cycle. R = 2′-
deoxyribose-5′-monophosphate; R’ = p-benzoyl-amino-l-glutamic acid.
At variance with TS that is present in some viruses and various organisms including humans,
FDTS is unique to bacteria [1–4]. Important human pathogens, including Helicobacter pylori, Borrelia
Burgdorferi, Treponema pallidum, Chlamydia species and Rickettsia species, rely only on FDTS for dTMP
biosynthesis [2,6,7]. On the other hand, human pathogenic bacteria such as Staphylococcus aureus,
Enterococcus faecalis and Pseudomonas aeruginosa, have only the thyA gene, expressing solely the
TS enzyme [2,6,7]. A third group of bacteria, possessing both thyA and thyX genes, has been
identified [2,6,7]. Bacillus anthracis, Clostridium botulinum, and Mycobacterium species are examples
of important human pathogens belonging to this group [2,6,7]. In view of their common biological
function, the reason concomitant expression of TS and FDTS occurs in these bacteria is not yet fully
understood. Studies on Mycobacterium tuberculosis have evidenced that the thyX gene is essential,
while the thyA deletion confers p-aminosalicylic acid resistance [6]. Furthermore, investigations on
multi-drug resistant strains of Mycobacterium tuberculosis, have shown up-regulation of the thyX gene,
responsible for FDTS overexpression [8].
Nowadays, the widespread diffusion of antibiotic resistance is an important health issue [9–12].
The major challenges are the identification of new microbial targets and the development of effective
antibiotic therapies able to treat resistant infections. For this purpose, FDTS represents a promising
target for the development of new antibiotics, since it has no counterpart enzyme in the human
host [13,14]. On the other hand, TS is highly conserved in human and bacteria creating limitations
for the development of inhibitors selectively targeting the bacterial enzyme [15]. Recent studies have
provided important new insights into the catalytic process of both methyltransferase enzymes [3,4].
Indeed, new mechanisms of action for TS and FDTS have been recently proposed [3,4], opening new
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perspectives for the development of antibacterial drugs targeting these enzymes. This review is aimed
to summarize the current understanding of structure and function of bTSs and FDTSs and the recent
progresses in the development of inhibitors targeting these enzymes in human pathogenic bacteria.
2. Bacterial Thymidylate Synthases (bTSs)
2.1. Structural Insights into bTSs from Human Pathogens
Few crystallographic structures of TSs from human pathogenic bacteria have been reported
to date. The structures of TSs from Mycobacterium tuberculosis (MtbTS; PDB id 3QJ7, unpublished
research), Staphylococcus aureus (SaTS; PDB id 4DQ1, unpublished research), Enterococcus faecalis (EfTS;
PDB id 3UWL [16]), Escherichia coli (EcTS; PDB id 1F4B [17]), Brucella melitensis (BmTS; PDB id 3IX6,
unpublished research), and Elizabethkingia anophelis (EaTS; PDB id 6AUJ, unpublished research) are
currently available in the Protein Data Bank (PDB), but limited information is reported in the literature.
TS works as an obligate homodimer since residues from both subunits contribute to create the
enzyme active site. Each subunit is composed of two domains, named large and small domains
(LD and SD, respectively, Figure 2a). The LD, representing the conserved core of the enzyme, has a
mixed α/β structure characterized by seven α-helices and eight β-strands (Figure 2a). A five-stranded
β-sheet in the LD of each subunit generates the dimer interface, a crucial area for the enzyme function
and for inter-subunit communication [18–20]. On the other hand, the SD is highly variable among
bTSs, in terms of amino acid composition and length (Figures 2b and 3a). The active site is a shallow
cavity embedded between the two domains, where the substrate and the cofactor bind in a sequential
order, relying on dUMP binding followed by CH2H4folate. A recent study has evidenced that the
binding order of substrate and cofactor is tightly controlled in EcTS, whereas it is less stringent for the
human enzyme (hTS) [21].
The substrate binding pocket is highly conserved among bTSs (Figures 2b and 3b). The dUMP
phosphate moiety is bound to four conserved arginine residues (Arg21, Arg166, Arg126′ and Arg127′ in
EcTS), two of them protruding in the active site from the cognate subunit (Arg126′ and Arg127′ in EcTS,
Figure 3b). The four-arginine cluster is pivotal to anchor the substrate in its pocket, indeed substitution
of these arginine residues impairs the enzyme catalytic activity [22–25]. This is also confirmed by the
recent evidence of poor catalytic efficiency displayed by the TS from the non-pathogenic bacterium
Vibrio parahaemolyticus, where Arg127′ is constitutively missing [26]. The correct orientation of the
dUMP uracil ring is ensured by a conserved asparagine (Asn177 in EcTS) [27]. The asparagine amide
moiety forms two H-bonds with the nitrogen N3 (position 3) and the ketone oxygen in position 4,
on the dUMP uracil (Figure 3b). Studies performed on EcTS have revealed that the removal of the
asparagine side chain disorganizes the substrate placement, drastically reducing the enzyme catalytic
activity [27]. The correct orientation of the substrate is further ensured by the H-bonds between the
dUMP ribose hydroxyl and conserved tyrosine and histidine residues (Tyr209 and His207 in EcTS;
Figure 3b). Recent evidence on EcTS has shown that this conserved tyrosine is pivotal to pre-organize
the active site for the hydride transfer in the last stages of the TS catalyzed reaction (the reaction
mechanism is detailed in Section 2.2) [28].
The cofactor binding site is also shared among bacterial TSs (Figures 2b and 3c). The pteridine
nitrogen N3 is H-bonded to the carboxylate group of a conserved aspartic residue (Asp169 in EcTS;
Figure 3c). Within the bTS active site, the cofactor is mainly stabilized by hydrophobic interactions,
indeed it entails a network of van der Waals contacts with a set of conserved hydrophobic residues
(Figures 2b and 3c). The cofactor is further H-bonded (both directly and through water mediated
interactions) with the backbone of the penultimate C-terminal residue (Figure 3c). The C-terminal
segment (residues 261–264 in EcTS) closes on the active site after cofactor binding, sealing the cavity.
The external portion of the active site is highly variable among bTSs, inducing slightly different
orientations of the terminal glutamate moiety of the cofactor, which entails mainly water-mediated
interactions in this area. Lys48 in EcTS is the only conserved residue that characterizes this site. Lys48
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forms a water-mediated interaction with the cofactor glutamate moiety, which has been proved to be
important during the enzyme catalysis [29].
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Figure 2. (a) Cartoon representation of the TS homodimer (MtbTS, PDB id 3QJ7, unpublished
research). The LD of Subunits A and B are colored light cyan and white, respectively. The SD
(residues 67–87, in MtbTS) is colored coral in both subunits. The position of the active site is indicated
by the presence of the substrate dUMP (in sticks, bla k carbon ). (b) Sequence alignment of TSs
from pathogenic bacteria and the human enzyme (hTS). Enterococcus faecalis TS (EfTS, UniProtKB:
Q834R3), Staphylococcus aureus TS (SaTS, UniProtKB: P67046), Brucella melitensis TS (BmTS, UniProtKB:
P67042), Escherichia coli TS (EcTS, UniProtKB: P0A884), Mycobacterium tuberculosis TS (MtbTS, UniProtKB:
P9WFR9), andElizabethkingia anophelisTS (EaTS, UniProtKB: A0A077EAN3); human TS (hTS, UniProtKB:
P04818). The present alignment includes only the TS sequences from human pathogenic bacteria for
which the structure has been characterized. The SD is highlighted in coral and the catalytic cysteine in
green. Conserved residues are indicated by asterisks. Residues forming the dimer interface and the
active site are indicated by “i” and “a”, respectively.
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Figure 3. (a) Superimposition among the SD of MtbTS (PDB id 3QJ7, unpublished research, coral
trace), SaTS (PDB id 4DQ1, unpublished research, gold trace), EfTS (PDB id 3UWL [16], cyan trace),
EcTS (PDB id 1F4B [17], green trace), BmTS (PDB id 3IX6, unpublished research, dark green trace),
and EaTS (PDB id 6AUJ, un ublished research, pink trace). (b) Conserved dUMP interactions within
the substrate binding pocket of the TS active site (EcTS sequence numbering). (c) Cofactor interactions
within the active site (EcTS sequence numbering). Only direct interactions are shown in Panels b and c
for clarity. (d) Active site view of the superimposition of bTS and hTS, evidencing the presence of an
unshared residu in the cofactor site, namely As 112 in hTS that replaces the conserved tryptophan
residue present in bTSs (Trp83 in EcTS). In all figures, oxygen atoms are colored red, nitrogen blue,
sulfur yellow, phosphorous magenta and halogen grey.
The residues responsible for substrate binding are highly conserved also in the human enzyme
(Figure 2b). However, the set of hydrophobic residues composing the cofactor site is altered in
hTS by the presence of Asn112 that replaces a tryptophan residue (Trp83 in EcTS) shared by bTSs
(Figures 2b and 3d). The presence of unshared residues in the active site of bacterial and human
enzymes is of key importance for the development of selective bTS inhibitors.
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2.2. Latest Updates on the TS Catalytic Mechanism
TS catalyzes the reductive methylation of dUMP to dTMP, using C2H4folate as co-substrate
(Scheme 1) [1,30]. The catalytic cysteine (Cys146 in EcTS; Figure 2b) is fundamental to activate the
substrate and to attract the methylene moiety according to an established mechanism (Steps 1 and 2,
Scheme 1) [3,31]. The thiol of the catalytic cysteine attacks the uracil C6 of dUMP leading to the
formation of a covalent adduct (Step 1) [3,31]. The uracil C5 is thus activated to attack the imine carbon
C11 of the cofactor (resulting from the aperture of the 5-membered ring of C2H4folate) forming the
ternary adduct (Step 2). The mechanism of methyl and hydride transfer from the cofactor has been
recently revised on the basis of new computational and experimental evidences [3,32–36]. According to
the traditional mechanism (Path A), the transfer of the proton from the uracil C5 generates a covalent
enolate intermediate (Step 3A). This stage is followed by the release of H4folate (through Hoffman
elimination, Step 4A). On the other hand, in the new mechanism (path B) the proton abstraction leads to
the cleavage of the covalent bond anchoring the uracil C6 to the cysteine thiol (Step 3B). Subsequently,
the intermediate undergoes 1–3 SN2 reaction, leading to the regeneration of the covalent bond to the
catalytic cysteine (Step 4B). The two mechanisms converge in the formation of the exocyclic methylene
intermediate, that undergoes a concerted hydride transfer and cleavage of the C-S bond (1–3 SN2
reaction, Step 5), preceding the formation of the products (Step 6).
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Scheme 1. Proposed mechanism for the TS catalyzed reaction. The traditional (A) and the recently
revised (B) paths for the central part of the reaction are displayed. R = 2′-deoxyribose-5′-monophosphate;
R’ = p-benzoyl-amino-l-glutamic acid. Adapted with permission from Kholodar, SA & Kohen A.
Noncovalent Intermediate of Thymidylate Synthase: Fact or Fiction? J. Am. Chem. Soc. 2016, 138,
8056–8059 [3]. Copyright 2016 American Chemical Society.
2.3. Asymmetry and “Half-Site Reactivity” in bTSs, a Still Open Debate
Several multi-subunit enzymes show the phenomenon of “half-site reactivity”. Strictly speaking,
half-si e reactivity occurs when the reaction w th a substrate shows a stoichiometry equal to one-half
the number of identical subunits in the multimer. Half-sit reactivity represents a form of egative
cooperativity between the protomers, in which binding of the substrates in one catalytic site prevents
catalysis in the partner subunit. Among bTSs, EcTS is the most widely studied, whereas very little is
known about TSs from other pathogenic bacteria. The presence of half-site reactivity in EcTS, was
suggested by kinetic studies, differential scanning and isothermal titration calorimetry and fluorescence
quenching experiments [29,30,37,38]. Nonetheless, recent studies on EcTS have provided evidence of
minimal or absent negative cooperativity in substrate and cofactor binding to both catalytic sites [18,39].
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Isothermal titration calorimetry (ITC) experiments have shown that the binding of substrate and
cofactor occurs in both enzyme subunits with essentially no cooperativity (only a minor effect is
observed in a temperature-dependent manner) [18]. On the other hand, NMR studies have evidenced
a tiny, but detectable, extent of negative cooperativity for substrate and cofactor binding in the
two EcTS protomers [18,39]. On the basis of these investigations, it has been proposed that EcTS is
characterized by a “silent” or “isoergonic” allostery towards dUMP and cofactor binding (meaning
that the two binding events have similar affinities but differ in ∆H, ∆S, and/or ∆Cp) [18,39]. NMR
studies have also highlighted a significant contribution of the TS dimer interface in inter-subunit
communication [39,40]. Meaningful chemical shift perturbations are observed across the dimer
upon the population of both dUMP sites, whereas only local changes are reported when dUMP
binds to only one site. The widespread perturbations induced by the second dUMP binding event
indicates inter-subunit communication between the two substrate sites (and the two catalytic cavities).
These perturbations involve the interface area covering the segment 146–153, Ala132, and residues
198–199 [40]. Therefore, any cooperativity is likely due to long-range, cross-interface effects, occurring
upon binding of dUMP in the second site once the first is already populated [39,40]. Very recently,
new evidence has been reported on EcTS, upon investigating the C-terminal deletion variant I264Am
(lacking the C-terminal Ile264) [19]. In TS enzymes, the C-terminal segment (residues 261–264 in EcTS)
rearranges, following the formation of the ternary adduct with substrate and cofactor, closing the
cavity and contributing to stabilize the active site during catalysis. The structure of EcTS I264Am
shows dimer asymmetry due to different configurations of the catalytic cavities both populated by
dUMP and the cofactor analogue inhibitor CB3717 (PDB id 6CDZ [19]; Figure 4a). Substrate and
inhibitor are correctly aligned to mimic a catalytically-competent configuration only in the active site
of one protomer (Figure 4a,b). On the other hand, the two compounds result slightly displaced in the
partner subunit adopting a non-catalytically-competent configuration (Figure 4a,b). This observation
supports half-site reactivity for EcTS (Figure 4a). In the structure of EcTS I264Am, changes are observed
in the interface area, suggesting that they mediate the inter-subunit communication and regulate
half-site reactivity. The most evident change concerns Phe149, facing itself on the partner subunit, for
which increased sidechain flexibility is observed in EcTS I264Am asymmetric dimers [19]. All together
these evidences suggest that in EcTS both active sites can be concomitantly populated by substrate
and cofactor, but the extent of negative cooperativity at the basis of the half-site reactivity is still
controversial [18,19,39,40]. However, all studies agree on the prominent role played by the dimer
interface on inter-subunit communication. NMR and X-ray crystallographic studies converge on the
involvement of the interface segment extending from the catalytic Cys146 to Tyr153 in inter-subunit
communication [19,40]. The existence of analogous mechanisms in TSs of other pathogenic bacteria is
still unknown.
In bTSs, the SD is highly variable in extension and structure, indeedEfTS andSaTS are characterized
by a more extended SD, including an additional segment of 50 amino acids (Figure 2b). This can induce
significant differences in asymmetric ligand binding and half-site reactivity among bTSs. The structural
characterization of EfTS has highlighted huge differences between the enzyme protomers, resulting
in highly asymmetric enzyme homodimers (PDB id 3UWL [16]; Figure 4c). One subunit adopts the
so-called closed conformation, in which the catalytic cavity is fully formed and the SD is structured,
whereas the partner protomer is in the open form, showing a widely unstructured active site and SD
(Figure 4c) [16]. Despite the structure of EfTS suggests that it could be a half-site reactive enzyme,
its cooperativity profile has still to be fully elucidated. Recent structural investigations have shown
that substrate binding in the open-subunit of EfTS induces the closure of the dUMP site, whereas the
rest of the catalytic cavity keeps the open conformation (PDB id 6QYA; Figure 4d) [41]. Therefore,
it has been proposed that the open/closed transition occurs in EfTS as biphasic process in which
dUMP binding triggers the closure of the substrate site whereas cofactor binding is required to fully
structure the catalytic cavity (Figure 4d). In the EfTS-dUMP complex asymmetric substrate binding
is consistently observed. On the other hand, the structural characterization of SaTS in complex with
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dUMP (SaTS; PDB id 4DQ1, unpublished research) shows symmetric ligand binding, having both
active sites populated by the substrate. Despite EfTS and SaTS have SDs of similar extension, they
display different behaviors, suggesting that it is not possible to delineate common mechanisms for
bTSs. Therefore, the recent evidences on EcTS half-site reactivity and inter-subunit communication
cannot be directly extended to all bacterial enzymes. The issues of asymmetric ligand binding and
half-site reactivity in bTSs of other pathogenic bacteria remain largely unknown and are worthy of
careful investigation.
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Active site view of the superimposition between the catalytically-competent configuration and the 
non-catalytically-competent configuration of EcTS I264Am homodimer. (c) Cartoon representation of 
the EfTS homodimer (Subunits A and B are colored white and light turquoise, respectively, the SD is 
colored turquoise in both subunits; PDB id 3UWL [16]). The EfTS homodimer is highly asymmetric. 
Subunit B is in the closed conformation, having the catalytic cavity fully formed, whereas the partner 
protomer is in the open form, showing a widely unstructured active site. The cofactor analogue 5-
Figure 4. (a) Cartoon representation of EcTS I264Am homodimer (Subunits A and B are colored white and
light turquoise, respectively; dUMP and CB3717 are shown in sticks, color coded according to the subunit;
PDB id 6CDZ [19]). In the active site of Subunit B, the substrate and the cofactor-like inhibitor CB3717
are correctly aligned to mimic a catalytically-competent configuration. On the contrary, in the partner
protomer the two mol cules assume a non-catalytically- ompetent configuration. The induced asymmetry,
generated in the EcTS dimer, supports the half-site reactivity of the enzyme. (b) Active site view of the
superimposition between the catalytically-competent configuration and the non-catalytically-competent
configuration of EcTS I264Am homodi er. (c) Cartoon representation of the EfTS omodimer (Subunits
A and B are colored white and light turquoise, respectively, the SD is colored turquoise in both subunits;
PDB id 3UWL [16]). The EfTS homodimer is highly asymmetric. Subunit B is in the closed conformation,
having the catalytic cavity fully formed, whereas the partner protomer is in the open form, showing a
widely unstructured active site. The cofactor analogue 5-formyl-tetrahydrofolate, 5-FTHF (in sticks, black
carbons), is entrapped in the active site of Subunit B (d) Active site view of the superimposition between
the open (white cartoon and carbons) and the closed (light turquoise cartoon and carbons) states of EfTS
(PDB id 3UWL [16]) and the EfTS–dUMP complex (purple cartoon and carbons; Cys197 is modified
as S-oxycysteine; PDB id 6QYA [41]). dUMP binding in open-state subunits induces the closure of the
substrate site (indicated by a dashed pink arrow), whereas cofactor binding is required to fully structure
the catalytic cavity. The movement of loop 18–26, determining the closure of the substrate site, is evidenced
by the shift of Arg22 (in sticks).
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3. Flavin-Dependent Thymidylate Synthases (FDTSs)
3.1. Structural Insights into FDTSs from Human Pathogens
The structural characterization of FDTSs from human pathogenic bacteria is limited to the enzymes
from Mycobacterium tuberculosis (MtbFDTS; PDB id 2AF6 [42]) and Helicobacter pylori (HpFDTS; PDB
id 3N3Y [43]). FDTS are homotetrameric proteins, with four identical subunits forming extensive
interactions (Figure 5a). Each subunit shows a complex fold, characterized by a central α/β domain
flanked by two helical domains, known as top and bottom domains. The central domain consists of a
four-stranded antiparallel β-sheet, flanked on one side by three α-helices. The four active sites are
located at the interface between three neighboring monomers, having residues from all three subunits
that contributes to create the catalytic cavity (Figure 5a; subunits contributing to each active site are
illustrated in the figure; Active site 1, composed of residues belonging to Subunits A, B and C, is used
for the structural description) [42–44]. FAD acquisition by FDTS was reported to occur inside cells,
during the expression of the protein. Therefore, the purified samples already included the cofactor in its
oxidized form as indicated by the peculiar yellow colorization of the protein solutions [42,43]. Within
each subunit, FAD adopts an extended conformation, covering a total surface area of ~490 Å2 [42,43].
The AMP adenine moiety of FAD is buried inside a deep pocket, whereas the AMP ribose faces the
ribose of the FAD bound to a neighboring subunit (ribose of FADA and FADB, belonging to Subunits
A and B, respectively, in Figure 5b; FADA is considered for the present description). The phosphate
group of AMP and the ribityl and phosphate moieties of flavinmononucleotide (FMN), belonging
to FADA, form H-bonds with the residues of the highly conserved FDTS motif RHR of Subunit A
(residues 95A–97A in MtbFDTS, Figure 5b; corresponding to 74A–76A in HpFDTS). These moieties are
also H-bonded with two further conserved residues belonging to Subunit B (Ser71B and Arg190B in
MtbFDTS, Figure 5b; corresponding to Ser50B and Arg165B in HpFDTS). Inside the active site, the FADA
isoalloxazine ring is H-bonded with the first arginine of the conserved RHR motif (Arg95A in MtbFDTS,
Figure 5b; corresponding to Arg74A in HpFDTS) and with the backbone of a residue belonging to the C
Subunit (Gln103C in MtbFDTS and Val82C in HpFDTS; interaction not shown in Figure 5b). The flavin
ring of FADA is stacked with the pyrimidine of dUMPC. The complex of MtbFDTS with the substrate
analogue FdUMP (PDB id 3GWC [44]) is shown in Figure 5b. FdUMP retains the same binding mode
of dUMP in the HpFDTS-dUMP complex (PDB id 3N3Y [43]). Notably, the dUMPC C5 is aligned to
the flavin N5 of FADA, separated by a short interatomic distance (<3.5 Å). The alignment of these
two atoms is fundamental during the FDTS catalyzed reaction. According to the revised reaction
mechanism (detailed in Section 3.2), the methyl is transferred from CH2H4folate to the FAD flavin
N5, that subsequently donates it to the dUMP C5 allowing the formation of the product dTMP. In
the catalytic cavity, the dUMP substrate (dUMPC) is further stabilized by the interactions with a set
of conserved residues (Arg95A and Arg199A, Arg87C, Ser105C and Arg107C in MtbFDTS, Figure 5b;
corresponding to Arg74A, Arg174A, Arg66C, Ser84C and Arg86C in HpFDTS). The dUMPC uracil C5
and the FADA flavin N5 are shielded from the solvent by a shared tyrosine (Tyr108C and Tyr87C in
MtbFDTS and HpFDTS, respectively), whose phenyl moiety forms a “lid” over the reactive positions
involved in the methyl transfer (Figure 5b).
The structure of MtbFDTS was reported also in complex with the second cofactor NADP+ that
occupies the same site of FAD and adopts an analogous binding mode (PDB id 2GQ2 [45]; Figure 5c).
The nicotinamide of NADP+ is accommodated inside the catalytic cavity in which it replaces the
isoalloxazine system of FAD (Figure 5c) [45]. It is worth noting that attempting to obtain the quaternary
complex MtbFDTS–FAD–BrdUMP–NADP+ by co-crystallization of the enzyme with both cofactors and
the substrate analogue BrdUMP, provided the structure of the binary complex MtbFDTS–NADP+ [45].
The mechanistic explanation of this behavior is not obvious, since it has been postulated that the
regeneration of the reduced flavin during the FDTS catalyzed reaction is mediated by NADPH.
Therefore, they should both bind to the enzyme during this stage. The structural characterization
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of FDTS in complex with both FAD and NADPH can provide key information on the mechanism of
reduced flavin regeneration which has still to be fully elucidated.
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Figure 5. (a) Cartoon representation of the FDTS homotetramer (MtbFDTS; Subunit A is colored dark
green, B light green, C pink, and D gold; PDB id 3GWC [44]). Subunits contributing to each active site
(numbered from 1 to 4) are illustrated in the figure. The Active site 1, composed of residues belonging
to Subunits A, B and C, is used for structural description. FAD and the substrate analogue FdUMP
are represented in spheres (of arbitrary radius, carbon atoms are color-coded according to the parent
subunit). (b) H-bonds (blue dashed lines) of FAD and FdUMP (in sticks, carbon atoms are color-coded
according to the parent subunit) with residues shared between MtbFDTS and HpFDTS (the MtbFDTS
sequence numbering is reported in the picture; PDB id 3GWC [44]). The Active site 1, composed of residues
belonging to Subunits A, B and C, is used for structural description in Panels b and c. (c) NADP+ (in sticks,
carbon atoms are color-coded according to the parent subunit) binding mode in the complex with MtbFDTS
(PDB id 2GQ2 [45]). (d) Active site view of the quaternary complex TmFDTS (white cartoon)–FAD (in
sticks, dark green carbons)–dUMP (in sticks, pink carbons)–CH2H4folate (in sticks, green carbons) (PDB id
4GT9 [46]). The isoalloxazine moiety of FAD is sandwiched between the dUMP uracil and the pteridine
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Structural information concerning the CH2H4folate binding mode in MtbFDTS and HpFDTS is
not available. However, the FDTS-CH2H4folate complex has been determined for Thermotoga maritima
FDTS (TmFDTS) [46]. The structure of the quaternary complex TmFDTS–FAD–dUMP–CH2H4folate
(PDB id 4GT9 [46]) shows the isoalloxazine moiety of FAD sandwiched between the dUMP uracil and
the pteridine of CH2H4folate (Figure 5d). In the structure, the pteridine N5 of CH2H4folate is perfectly
aligned with both the flavin N5 of FAD and the uracil C5 of dUMP. This configuration of the active
site allows the FAD-mediated methyl transfer from CH2H4folate to dUMP in accord with the revised
reaction mechanism described in Section 3.2.
3.2. FDTS Reaction Mechanism
The combined results of mass spectrometry, NMR and X-ray crystallographic studies on FDTSs
have led Kohen and coworkers to formulate a new reaction mechanism for this class of enzymes,
reported in Scheme 2 [4]. The proposed multistep process for FDTSs starts with the protonation of
C2H4folate (Step 1), leading to the formation of a Schiff base, that is activated to transfer the methyl
moiety to the flavin N5 of the reduced cofactor FADH (Step 2). In the resulting covalent adduct,
the protonation of the folate N5 is mediated by an unknown species (Step 3). Once the methyl moiety
is transferred on the FAD cofactor, a new Schiff base is formed. The Schiff base can react with the
polarized dUMP (Step 4) to form a covalent intermediate (Intermediate I1) in which the methyl group
bridges the FADH N5 and the dUMP C5. The generation of the intermediate I1 is accompanied by the
release of H4folate from its site (Step 4). The intermediate I1 undergoes protonation on the flavin N5 by
an unknown species (Step 5) which precedes the abstraction of the proton from the dUMP C5, still by
an uncharacterized actor (Step 6). The deprotonation of the C5 induces the transfer of the methylene
group on dUMP (Step 6), leading to the formation of the Intermediate I2. I2 undergoes a redox reaction
in which flavin is oxidized at the expenses of the nucleotide that is reduced to dTMP (Step 7) and
subsequently released from its site. The reduced flavin is regenerated by the oxidation of NADPH to
NADP+ in a second redox reaction (Step 8).
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4. Inhibitors of TSs and FDTSs from Human Pathogenic Bacteria
4.1. Inhibitors of Bacterial TS from Human Pathogens
The main difficulty to develop bTS inhibitors is related to selectivity. The active sites of human
and bacterial TSs are highly conserved, the main difference being one unshared residue in the cofactor
binding site. Furthermore, variable conformational changes have been characterized in bTSs that are
different from those observed in the human enzyme. bTSs shift between open and closed conformations
involving structural rearrangements that are peculiar of each bacterial enzyme [16,19,39]. However,
hTS switches between the active and inactive conformations, by shifting the catalytic cysteine from
the catalytic cavity to the dimer interface [47,48]. In the last decade, different molecular classes have
been investigated to selectively target TSs of human pathogenic bacteria. In silico studies combined
with structural investigations led to the identification of some phtalimide derivatives as selective
bTS inhibitors [49,50]. Compounds 6A and (R)-40 (Figure 6a) resulted effective towards EfTS (Ki of
7.0 µM and 13.0 µM, respectively), without affecting the human enzyme [49,50]. The structure of EfTS
in complex with a representative phtalimide derivative showed that Compound 12 (Figure 6a, PDB
id 4O7U [50]) populates the cofactor site regardless the binding of the substrate (Figure 6b). This
configuration is unusual in TS, since cofactor-like inhibitors normally populate their site in presence
of dUMP (ternary complexes). The six-membered aromatic ring of phtalimide forms a close van der
Waals contact with the EfTS Trp84 (Figure 6b). This residue, shared among bTSs, is replaced by an
asparagine (Asn112) in human TS (Figure 3d), providing basis to explain the selectivity profile of
these molecules.
Phenolnaphthalein derivatives were also proposed as selective bTS inhibitors [51]. Compounds
4B and 9B (Figure 6a) showed relevant selectivity, being active towards EcTS (Ki of 6.4 µM and 6.5 µM,
respectively) and completely inactive against hTS [51]. Attempting to further improve this class of
compounds through the generation of naphthofuranon derivatives resulted in an almost complete loss
of selectivity, being also active towards hTS [52]. The structure of EcTS obtained in complex with a
representative member of this series, revealed that Compound 3 (Figure 6a, PDB id 4LRR) binds inside
the catalytic cavity inducing the rotation of dUMP outside the substrate binding pocket (Figure 6c) [52].
In vitro analysis on pyrimidine-5-carbonitrile derivatives [53] and on the ruthenium-based complex
[(C6H6)RuL(N,N)Cl] [54] reported antimicrobial activity on S. aureus and other human pathogenic
bacteria. In silico studies have identified them as potential SaTS inhibitors [53,54]; however no
experimental evidences have proven their activity towards SaTS.
Recently, the structures of MtbTS in complex with raltitrexed and pemetrexed (Figure 7a), two
known hTS inhibitors, have been reported in the PDB (PDB ids 4FOX and 4FQS, respectively;
unpublished research). The comparison between the structures MtbTS–dUMP–raltitrexed and
hTS–dUMP–raltitrexed (PDB id 5X5Q [48]) shows the inhibitor bicyclic system in two different
orientations inside the catalytic cavities of the two enzymes (Figure 7b). However, the binding mode
of pemetrexed is almost conserved in the active sites of MtbTS and hTS (Figure 7c). Differences in
the ligand binding mode between MtbTS and hTS are exploitable for the development of selective
bTS inhibitors.
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4.2. FDTS Inhibitors towards Human Pathogenic Bacteria
Microbial FDTSs have no structural homology with hTS, being highly divergent in the
configurations of the active sites and in their catalytic mechanisms. Therefore, FDTSs represent
promising targets for the development of new antimicrobial drugs.
Natural compounds are an important source to identify new chemical scaffolds. A library of more
than 2300 natural compounds was screened towards FDTSs from various pathogenic bacteria (including
HpFDTS, MtbFDTS, and Chlamydia trachomatis FDTS, CtFDTS) [56]. In this study, 1,4-naphthoquinone
(NQ) derivatives were identified as FDTS inhibitors. Subsequent studies on the NQ derivative C8–C1
(Figure 8a) showed that it is a potent inhibitor of HpFDTS (estimated Ki of 367 nM), displaying
meaningful antimicrobial activity on H. pylori (MIC 10 µg mL−1) [57]. The structure of C8-C1 in
complex with the FDTS from Paramecium bursaria chlorella virus (PBCV1 FDTS; having an almost
conserved active site with respect to bacterial FDTSs) showed that the compound occupies the catalytic
cavity, replacing the dUMP uracil (Figure 8b; PDB id 4FZB [56]).
NQ derivatives were further developed, resulting in two compounds with improved potency
towards HpFDTS [57]. Compound 010-C (Figure 8a) was the most potent HpFDTS inhibitor, having
a Ki in the low nano-molar range (Ki of 28 nM) [57]. These improved NQ derivatives resulted also
effective towards H. pylori (MIC ranging from 0.625 to 10 µg mL−1). The three most potent compounds
of this series were also investigated in vivo using a mouse model for H. pylori infection. The compounds
were tolerated in mice, but displayed a modest antibacterial effect [57].
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In 2016, in silico studies on FDTS were combined with structural investigations leading to the
identification of a new molecular scaffold exploitable for the development of novel FDTS inhibitors [58].
The binding mode of Compound 7 (Figure 8a, 6% inhibition at 100 µM towards MtbFDTS) was clarified
in complex with the FDTS from the non-pathogenic Thermotoga maritima (TmFDTS, PDB id 5CHP [58]).
The structure shows that Compound 7 occupies the dUMP site within the catalytic cavity. Biochemical
assays performed on hTS, evidenced the ineffectiveness of the compound on this target, indicating this
scaffold useful for the development of novel FDTS inhibitors.
Recently, an high-throughput screening has been performed on MtbFDTS, using a library of
40,000 compounds [59]. In silico studies have led to the identification of 1,4-benzoxazine derivatives as
FDTS inhibitors. Further investigations have proven that Compound B1-PP146 (unreported chemical
structure) was the most potent 1,4-benzoxazine derivative of this series. This compound is effective on
MtbFDTS (IC50 of 0.71 µM), displaying competitive inhibition against CH2H4folate [59].
4.3. dUMP-Like Inhibitors towards Human Pathogenic Bacteria Expressing Both TS and FDTS Enzymes
Bacillus anthracis, Clostridium botulinum, and Mycobacterium species are examples of human
pathogenic bacteria expressing both TS (thyA gene) and FDTS (thyX gene) enzymes [2]. Studies
performed on Mycobacterium tuberculosis showed that the thyX gene is essential for bacteria survival
and its overexpression was observed in multi-drug resistant strains [6,8]. However, the thyA gene was
reported less essential for M. tuberculosis but connected with the resistance to p-aminosalicylic acid [6].
The effects of FDTS inhibition on bacteria expressing both methyltransferase enzymes have to be fully
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elucidated and the potential involvement of TS as metabolic bypass to FDTS inhibition is not excluded.
The ability of these enzymes to recognize the same substrate suggested its analogue FdUMP (Figure 9a)
as dual TS–FDTS inhibitor [60,61]. Indeed, FdUMP was reported as potent inhibitor of both MtbTS
(Ki of 2 nM) and MtbFDTS (Ki 100 nM) (Figure 9b,c), exhibiting also a remarkable antimycobacterial
activity (MIC 3.1 µM) [60,61].Molecules 2019, 24, x 18 of 23 
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I 2011, a series of 5-substituted-dUMP analogues was probed towards MtbFDTS and MtbTS [62].
Compound 1 (Figure 9a) resulted the most potent MtbFDTS inhibitor (IC50 of 0.91 µM), showing no
noticeable activity on MtbTS (IC50 > 50 µM) [62]. The replacement of dUMP with 6-aza-dUMP in a
new series of 5-substituted derivatives induced a drop of their potency towards MtbFDTS (maximal
inhibition of 40% at 50 µM), resulting inactive also against MtbTS [63]. Analogously, the replacement of
the nucleotide with an acyclic nucleoside phosphonate moiety (ANP derivatives) reduced the activity
towards MtbFDTS (maximal inhibition of 43% at 50 µM) [64].
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Structure-activity relationship analysis combined with in silico studies led to the development
of 5-undecyloxymethyl-dUMP (Figure 9a), for which an IC50 of 8.32 µM against MtbFDTS was
reported [65]. On the other hand, no detectable inhibition was observed on MtbTS (up to concentrations
of 100 µM) [65]. This compound, together with other derivatives of this series, displayed a significant
antibacterial activity (MIC 10–20 µg mL−1) towards two mycobacterial strains, the virulent laboratory
H37Rv strain and the multi-drug resistant MS-115 [66].
Very recently, a further series of nucleotide analogues has been investigated [67]. Various
5-modified 6-aza- and 2-thio-6-aza-2′-deoxyuridine derivatives have shown a significant antibacterial
activity on important human pathogens, including Mycobacterium smegmatis, Staphylococcus aureus and
Pseudomonas aeruginosa [67]. Docking studies have predicted that they target MtbFDTS. Nonetheless,
their activity on Staphylococcus aureus and Pseudomonas aeruginosa, lacking the thyX gene, strongly
suggests that these compounds inhibit other bacterial enzymes.
5. Conclusions
Methyltransferase enzymes of human pathogenic bacteria represent important targets for the
development of new antibiotic drugs. The catalytic processes of TS and FDTS have been recently
revised, but their mechanisms of action are not yet fully elucidated. For bTSs, half-site reactivity
is still an open debate. Recent insights obtained on EcTS are somehow controversial [18,19,39,40],
suggesting that deeper investigations are required to unveil the extent of inter-subunit cooperativity
in this enzyme. The TS dimer interface area has been shown to play a major contribution in the
inter-subunit communication occurring between the two holoenzyme halves during the catalytic
process. The TS dimer interface is crucial for the enzyme activity, but its potential as drug-targetable
area is yet unexplored for bacterial enzymes.
FDTSs represent a promising target for development of new antibacterial drugs since they have
no human counterpart enzymes. On the other hand, in FDTS, the mechanism of the redox reaction
responsible for the regeneration of reduced flavin is not fully elucidated. During this process, flavin
is reduced at the expenses of NADPH that is oxidized to NADP+. Understanding how FAD and
NADPH interact with FDTS during this stage of the catalytic reaction would represent a breakthrough
to elucidate the mechanism by which the flavin cofactor is regenerated by these enzymes.
The development of FDTS-targeting molecules has led to the identification of potent inhibitors.
Nonetheless, the in vivo properties of these compounds have to be improved to achieve suitable drug
candidates. Targeting this enzyme is crucial not only in human pathogens relying only on FDTS,
but also in those expressing both FDTS and TS enzymes. Although blocking the FDTS activity is
pivotal, the expression of TS could provide a metabolic bypass to FDTS inhibition, leading to resistance.
The importance of developing bTS inhibitors is further evidenced by the existence of important human
pathogens relying only on TS. The high conservation of the active site among bacterial and human
TSs constitutes an important issue for the design of selective bTS inhibitors. Relevant steps forward
have been recently reported opening new perspectives for the development of effective and selective
bTS-targeting drugs. The recent structural evidence acquired on bTSs from human pathogenic bacteria
has also highlighted prominent differences in the conformational flexibility among human and bacterial
enzymes, yet unexplored for the design of selective bTS inhibitors.
These are promising results; however, more efforts are required to obtain drug candidates targeting
bTS and FDTS enzymes.
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Abbreviations
The following abbreviations are used in the manuscript:
dTMP 2′-deoxythymidine-5′-monophosphate
dUMP 2′-deoxyuridine-5′-monophosphate
TS thymidylate synthase
DHFR dihydrofolate reductase
FDTS flavin dependent thymidylate synthase
CH2H4folate N5,N10-methylene-5,6,7,8,-tetrahydrofolate
H2folate dihydrofolate
H4folate tetrahydrofolate
FAD flavin adenine dinucleotide
NADPH nicotinamide adenine dinucleotide phosphate
PDB Protein Data Bank
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